Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review
Over the past 20 years, there has been a paradigm shift in the care of patients with non-small cell lung cancer (NSCLC), who now have a range of systemic treatment options including targeted therapy, chemotherapy, immunotherapy (ICI), and antibody–drug conjugates (ADCs). A proportion of these cancer...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/3/527 |
| _version_ | 1797318992781639680 |
|---|---|
| author | David John McMahon Ronan McLaughlin Jarushka Naidoo |
| author_facet | David John McMahon Ronan McLaughlin Jarushka Naidoo |
| author_sort | David John McMahon |
| collection | DOAJ |
| description | Over the past 20 years, there has been a paradigm shift in the care of patients with non-small cell lung cancer (NSCLC), who now have a range of systemic treatment options including targeted therapy, chemotherapy, immunotherapy (ICI), and antibody–drug conjugates (ADCs). A proportion of these cancers have single identifiable alterations in oncogenes that drive their proliferation and cancer progression, known as “oncogene-addiction”. These “driver alterations” are identified in approximately two thirds of patients with lung adenocarcinomas, via next generation sequencing or other orthogonal tests. It was noted in the early clinical development of ICIs that patients with oncogene-addicted NSCLC may have differential responses to ICI. The toxicity signal for patients with oncogene-addicted NSCLC when treated with ICIs also seemed to differ depending on the alteration present and the specific targeted agent used. Developing a greater understanding of the underlying reasons for these clinical observations has become an important area of research in NSCLC. In this review, we analyze the efficacy and safety of ICI according to specific mutations, and consider possible future directions to mitigate safety concerns and improve the outcomes for patients with oncogene-addicted NSCLC. |
| first_indexed | 2024-03-08T03:59:26Z |
| format | Article |
| id | doaj.art-3faad7767b574f93af5d8ed565bffbd3 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T03:59:26Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-3faad7767b574f93af5d8ed565bffbd32024-02-09T15:08:53ZengMDPI AGCancers2072-66942024-01-0116352710.3390/cancers16030527Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative ReviewDavid John McMahon0Ronan McLaughlin1Jarushka Naidoo2Trinity St James’s Cancer Institute, St. James’s Hospital, James’s Street, D08 NHY1 Dublin, IrelandSt. Vincent’s University Hospital, D04 T6F4 Dublin, IrelandDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USAOver the past 20 years, there has been a paradigm shift in the care of patients with non-small cell lung cancer (NSCLC), who now have a range of systemic treatment options including targeted therapy, chemotherapy, immunotherapy (ICI), and antibody–drug conjugates (ADCs). A proportion of these cancers have single identifiable alterations in oncogenes that drive their proliferation and cancer progression, known as “oncogene-addiction”. These “driver alterations” are identified in approximately two thirds of patients with lung adenocarcinomas, via next generation sequencing or other orthogonal tests. It was noted in the early clinical development of ICIs that patients with oncogene-addicted NSCLC may have differential responses to ICI. The toxicity signal for patients with oncogene-addicted NSCLC when treated with ICIs also seemed to differ depending on the alteration present and the specific targeted agent used. Developing a greater understanding of the underlying reasons for these clinical observations has become an important area of research in NSCLC. In this review, we analyze the efficacy and safety of ICI according to specific mutations, and consider possible future directions to mitigate safety concerns and improve the outcomes for patients with oncogene-addicted NSCLC.https://www.mdpi.com/2072-6694/16/3/527immunotherapyoncogene-addictedoncogene-addicted non-small cell lung cancerEGFRALKKRAS |
| spellingShingle | David John McMahon Ronan McLaughlin Jarushka Naidoo Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review Cancers immunotherapy oncogene-addicted oncogene-addicted non-small cell lung cancer EGFR ALK KRAS |
| title | Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review |
| title_full | Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review |
| title_fullStr | Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review |
| title_full_unstemmed | Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review |
| title_short | Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review |
| title_sort | is immunotherapy beneficial in patients with oncogene addicted non small cell lung cancers a narrative review |
| topic | immunotherapy oncogene-addicted oncogene-addicted non-small cell lung cancer EGFR ALK KRAS |
| url | https://www.mdpi.com/2072-6694/16/3/527 |
| work_keys_str_mv | AT davidjohnmcmahon isimmunotherapybeneficialinpatientswithoncogeneaddictednonsmallcelllungcancersanarrativereview AT ronanmclaughlin isimmunotherapybeneficialinpatientswithoncogeneaddictednonsmallcelllungcancersanarrativereview AT jarushkanaidoo isimmunotherapybeneficialinpatientswithoncogeneaddictednonsmallcelllungcancersanarrativereview |